High Barriers To Entry For Biogenerics Will Lead To Lower Cost Savings – Duke
Challenges facing potential manufacturers of follow-on biologics such as a higher cost of entry and initially slower uptake will result in lower cost savings than those seen with the launch of small molecule generics, according to Duke University economist Henry Grabowski
You may also be interested in...
FDA's decision to develop guidance for development of follow-on versions of biologics approved under the Food, Drug & Cosmetic Act indicates the agency has accepted section 505(b)(2) of the FD&C Act as a viable pathway for approval of such products
Legislation to create a pathway for FDA approval of generic biologics should be attached to the reauthorization of the Prescription Drug User Fee Act, Sen. Charles Schumer, D-N.Y., said at a Feb. 14 press conference announcing reintroduction of the bill
Creating a way for FDA to approve follow-on biologics could lead to savings of more than $14 billion for Medicare Part B from fiscal 2007 to 2016, according to a "preliminary assessment" that the Pharmaceutical Care Management Association released Jan. 4